Last reviewed · How we verify
Zilbrix-Hib
Zilbrix-Hib is a conjugate vaccine that protects against Haemophilus influenzae type b and diphtheria, tetanus, and pertussis.
Zilbrix-Hib is a conjugate vaccine that protects against Haemophilus influenzae type b and diphtheria, tetanus, and pertussis. Used for Haemophilus influenzae type b disease prevention, Diphtheria prevention, Tetanus prevention.
At a glance
| Generic name | Zilbrix-Hib |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating the body's immune system to produce antibodies against these pathogens, thereby preventing infection. The vaccine is composed of inactivated or attenuated pathogens or their components, which are combined with a carrier protein to enhance immune response. This conjugate vaccine is administered via injection to provide long-lasting immunity against these serious bacterial infections.
Approved indications
- Haemophilus influenzae type b disease prevention
- Diphtheria prevention
- Tetanus prevention
- Pertussis prevention
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Irritability
Key clinical trials
- Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™ (PHASE3)
- Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers (PHASE2)
- Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zilbrix-Hib CI brief — competitive landscape report
- Zilbrix-Hib updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI